evipedia.ai ← Back

Cathelicidin LL-37 for Health & Longevity

Evidence Review created on 08/06/2026 using AI4L / Opus 5

Also known as: LL-37, LL37, hCAP18, hCAP-18, CAMP, Cathelicidin Antimicrobial Peptide, FALL-39

Motivation

Cathelicidin LL-37 is the only peptide of its family made by the human body. It is a short chain of 37 amino acids, stored in white blood cells and in the cells lining the skin, gut, and airways, and released when tissue is injured or invaded. Once free, it breaks open bacterial membranes and calls other immune cells to the site.

Because the body produces more of it when vitamin D is plentiful, it became the most cited explanation for why vitamin D status tracks with resistance to infection. Interest has since moved past that. Synthetic LL-37 is now sold by peptide suppliers and used on the skin or by injection by people seeking faster wound repair. Meanwhile, researchers studying inflammatory disease keep finding the same peptide sitting at the center of the damage.

This review examines what is known about cathelicidin LL-37: how it works, what happens when it is raised or supplied from outside, where the evidence is solid, and where the same molecule cuts both ways.

Benefits - Risks - Protocol - Conclusion

This section collects high-level, substantive treatments of cathelicidin LL-37 that give an orienting overview of the peptide, its biology, and its clinical significance.

  • LL-37, the only human member of the cathelicidin family of antimicrobial peptides - Dürr et al., 2006

    The foundational narrative review of the peptide, covering its gene, processing, three-dimensional structure, and membrane-disrupting behavior. It remains the clearest single explanation of why a small positively charged helix kills bacteria preferentially over human cells.

  • A comprehensive summary of LL-37, the factotum human cathelicidin peptide - Vandamme et al., 2012

    A wide-angle survey of everything LL-37 does beyond killing microbes, including chemotaxis, wound closure, angiogenesis, and endotoxin neutralization. It is the best starting point for understanding why one short peptide has so many apparently unrelated effects.

  • Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer - Chen et al., 2018

    A review that sorts the tumor-promoting and tumor-suppressing effects of LL-37 by tissue type and by the surface receptor engaged in each. It is essential for anyone weighing the peptide’s cancer risk, because the direction of effect is not uniform.

  • Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease - Miao et al., 2024

    A recent review pulling together the cardiovascular strand of LL-37 biology across atherosclerosis, thrombosis, and cardiac hypertrophy. It supplies the context that a peptide framed as protective also participates in the disease process that kills most people.

  • Optimal Skin Protection with Vitamin D - Life Extension

    A consumer-facing article that explains, in accessible terms, how vitamin D drives LL-37 production in skin and what the peptide does there, including microbial control, immune cell recruitment, epithelial repair, and new blood vessel formation. It is useful as a plain-language bridge into the vitamin D–cathelicidin relationship.

Content from four of the five prioritized expert platforms could not be included. Searches of foundmyfitness.com, peterattiamd.com, hubermanlab.com, and chriskresser.com returned no article, episode, or presentation that addresses cathelicidin LL-37 in substantive depth; where the peptide appears at all, it is a single clause inside broader vitamin D or immune content. Life Extension is the only prioritized source with material meeting the depth threshold.

Grokipedia

  • Cathelicidin antimicrobial peptide

    The dedicated encyclopedia entry covering the cathelicidin family across vertebrates, the conserved cathelin domain, and the processing of the human precursor into LL-37. It is a fast orientation to nomenclature and comparative biology before reading the primary literature.

Examine

No Examine article exists for cathelicidin LL-37. A direct search of examine.com for both “LL-37” and “cathelicidin” returned zero results. This is expected: Examine covers dietary supplements and nutrients sold for oral use, whereas cathelicidin LL-37 is an injectable and topical investigational peptide that is not marketed as a dietary supplement and is not an approved medication in any jurisdiction.

ConsumerLab

No ConsumerLab article exists for cathelicidin LL-37. ConsumerLab tests and reviews commercially sold dietary supplements and foods; cathelicidin LL-37 is an investigational peptide sold only through research-chemical channels, so it falls outside the scope of that testing program and no product review, clinical update, or answer covers it.

Systematic Reviews

This section lists systematic reviews and meta-analyses that pooled human data on cathelicidin LL-37 across clinical settings.

Mechanism of Action

Cathelicidin LL-37 is produced from a single gene, CAMP (cathelicidin antimicrobial peptide, the gene that encodes the human cathelicidin precursor), located on chromosome 3p21.3. The gene product is hCAP18 (human cationic antimicrobial protein of 18 kilodaltons), an inactive precursor consisting of a signal sequence, a conserved cathelin-like domain, and the active C-terminal peptide. hCAP18 is stored in the specific granules of neutrophils (the most abundant white blood cell) and produced by keratinocytes, monocytes, mast cells, natural killer cells, and the epithelium of the gut, airway, and reproductive tract.

Activation requires proteolytic cleavage, and the enzyme doing the cutting determines the product. In neutrophils, proteinase 3 releases the canonical 37-residue peptide. In skin, the serine proteases kallikrein-5 and kallikrein-7 generate both LL-37 and shorter fragments such as RK-31 and KS-30 that have different biological activity. In vaginal fluid, the aspartic protease gastricsin generates a distinct 38-residue peptide. This processing step is where several disease states diverge from normal physiology.

The mature peptide is 37 amino acids beginning with two leucines, carries a net charge of roughly +6, and folds into an amphipathic alpha-helix — one face positively charged, the other water-repelling. Its principal actions are:

  • Direct membrane disruption: The cationic face is drawn electrostatically to the anionic phospholipids and lipopolysaccharide (LPS, the outer-membrane molecule of gram-negative bacteria that triggers inflammation) of microbial surfaces, then inserts and forms transmembrane pores or a surface “carpet” that collapses membrane integrity. Human cell membranes carry no net surface charge and are cholesterol-rich, which confers partial but not absolute selectivity.
  • Biofilm inhibition: At concentrations far below those needed to kill, LL-37 suppresses quorum-sensing gene expression and attachment, preventing biofilm formation rather than killing established organisms.
  • Chemotaxis and immune cell recruitment: LL-37 signals through FPR2 (formyl peptide receptor 2, a surface receptor that directs immune cells toward sites of damage) to draw neutrophils, monocytes, T cells, and eosinophils into tissue, and through P2X7 (a cell-surface sensor that detects the molecules released by damaged cells) and EGFR (epidermal growth factor receptor, a switch that drives cell growth and migration) transactivation to promote keratinocyte migration and new blood vessel growth.
  • Endotoxin neutralization: By binding lipid A directly, LL-37 prevents LPS from engaging TLR4 (toll-like receptor 4, the sensor that initiates the inflammatory response to gram-negative bacteria), damping cytokine release.
  • Alarmin and nucleic-acid chaperone activity: LL-37 complexes with fragments of a person’s own DNA and RNA and carries them into endosomes, where they engage TLR9 and TLR7/8 in plasmacytoid dendritic cells that would otherwise ignore self-derived material. This converts an antimicrobial peptide into an autoimmunity trigger and also induces the inflammatory signal IL-36γ (interleukin-36 gamma) in skin cells.

Regulation of the gene is the most consequential feature for anyone attempting to raise LL-37 without injecting it. The CAMP promoter contains a vitamin D response element — a DNA sequence bound by the vitamin D receptor (VDR, the nuclear protein through which vitamin D switches genes on) — and 1,25-dihydroxyvitamin D strongly upregulates the gene in myeloid cells (Gombart et al., 2005). Critically, this response element arose from a primate-specific mobile DNA insertion and does not exist in rodents, so mouse cathelicidin biology cannot be assumed to model the human vitamin D connection. A second, vitamin D-independent route runs through inhibition of histone deacetylases (the enzymes that keep DNA tightly wound and genes switched off, so blocking them makes genes easier to read): butyrate, a short-chain fatty acid produced by gut bacteria from fiber, and its pharmaceutical analog phenylbutyrate both induce CAMP transcription this way.

Two competing mechanistic accounts of LL-37 remain unresolved. The classical view holds that direct microbial killing is the peptide’s primary function. The competing view holds that at physiological salt concentration, and in the presence of serum, direct killing is largely abolished — LL-37 binds apolipoprotein A-I in high-density lipoprotein (HDL, the cholesterol-carrying particle often called “good cholesterol”) and is thereby sequestered — so its real role in the body is immune signaling rather than antisepsis. Both camps cite the same in vitro assays run under different ionic conditions. The observation that people from the original Kostmann severe congenital neutropenia (an inherited disorder in which the body makes far too few of the main infection-fighting white blood cells) family who lack LL-37 develop severe periodontal disease despite normalized neutrophil counts (Carlsson et al., 2006) supports a genuine antimicrobial role at mucosal surfaces, while the salt-sensitivity data support the signaling account in plasma. The two are not mutually exclusive, and the site of action likely decides which dominates.

As a pharmacological agent, LL-37 behaves as a peptide rather than a small molecule. It has no cytochrome P450 metabolism (the liver enzyme family that clears most conventional drugs); elimination is proteolytic degradation to constituent amino acids by serine proteases, with trypsin fully degrading synthetic LL-37 within 6 hours at concentrations as low as 10 ng/mL, while matrix metalloproteinase-9 does not cleave it and chronic wound fluid degrades it only slowly (Grönberg et al., 2011). Bacterial proteases including Pseudomonas aeruginosa elastase and staphylococcal aureolysin also inactivate it. No formal human pharmacokinetic study of administered LL-37 has been published, so the circulating half-life of injected peptide is unknown; free peptide in plasma is expected to be cleared within minutes because of protease susceptibility and binding to apolipoprotein A-I and albumin. Tissue distribution after topical or intratumoral administration is essentially local. Selectivity for microbial over human membranes is real but modest, with cytotoxicity toward human keratinocytes and fibroblasts appearing above roughly 25–50 µM and hemolysis (rupture of red blood cells) above roughly 100 µM.

Historical Context & Evolution

LL-37 was not invented as a therapy. It was discovered in 1995 by two groups working independently on human bone marrow complementary DNA, and was initially named FALL-39 after the first four residues of what was then thought to be a 39-amino-acid peptide; correction of the cleavage site yielded the present name. Its original scientific purpose was descriptive — to characterize an endogenous effector of innate immunity — and its earliest translational framing was as a template for a new antibiotic class at a time when resistance to conventional antibiotics was accelerating.

The reasons it came to be considered for health optimization emerged over the following two decades:

  • The Kostmann observations (2002–2006). Patients from the original Swedish severe congenital neutropenia kindred normalized their neutrophil counts on growth factor therapy yet continued to suffer severe periodontitis. Their neutrophils were found to be deficient in LL-37, and three of four surviving patients had periodontal disease despite professional dental care, with one losing 15 permanent teeth by age 27. The actual finding — a specific peptide deficiency tracking a specific clinical failure despite adequate cell numbers — is what established LL-37 as functionally non-redundant in humans.
  • The vitamin D connection (2005–2006). The demonstration that the CAMP promoter carries a vitamin D response element, and that myeloid cells strongly upregulate the gene in response to active vitamin D, supplied a concrete molecular explanation for the century-old association between sunlight, vitamin D, and resistance to tuberculosis. Work published the following year showed that engaging toll-like receptors on macrophages induces the vitamin D receptor and the activating enzyme, closing the loop from pathogen recognition to peptide production to mycobacterial killing.
  • The reversal (2007). In the same year, two findings recast the peptide. One showed that LL-37 forms complexes with a person’s own DNA that break tolerance and drive interferon production by plasmacytoid dendritic cells in psoriatic skin (Lande et al., 2007). The other showed that people with rosacea express abnormally high cathelicidin and, more importantly, abnormally processed cathelicidin fragments, and that injecting those fragments into mouse skin reproduces the inflammation while deleting the cathelicidin gene abolishes it (Yamasaki et al., 2007).
  • Clinical development and its limits (2011–2023). A Swedish company developed a topical formulation and ran the first randomized controlled trial (RCT — a study in which participants are randomly assigned to treatment or comparison groups) of the peptide in humans, in venous leg ulcers. The same developer then ran a 148-participant multicentre phase IIb trial in the same indication, which reported in 2021 that neither concentration beat placebo in the full study population (Mahlapuu et al., 2021); that failure, not a safety signal, is what stalled the programme. A phase 1/2 intratumoral trial in melanoma opened at a United States cancer center in 2015 and closed in 2020 having enrolled 4 of a planned 36 participants. An academic group in Jakarta ran a separate, independently funded RCT of an LL-37 cream in diabetic foot ulcers and reported it in 2023. No LL-37 product has been approved anywhere.
  • Entry into the peptide market (2020s). Synthetic LL-37 became available through research-chemical suppliers and entered the injectable-peptide culture that also carries growth-hormone secretagogues and tissue-repair peptides, without any of the human dosing, pharmacokinetic, or safety data that would ordinarily precede such use.

Two claims from this history deserve careful handling rather than repetition as settled fact. The first is the early assertion that antimicrobial peptides are inherently “resistance-proof” because they attack membrane architecture rather than a single protein target. That claim has been challenged: staphylococci and other organisms modify membrane charge through the mprF and dltABCD systems to repel cationic peptides, several species secrete proteases that degrade LL-37, and serial passage in the laboratory does select for reduced susceptibility. It has also been defended: clinically significant, transmissible resistance to host defense peptides remains rare after hundreds of millions of years of host-microbe coevolution, and the resistance mechanisms identified are typically costly to the organism. Both bodies of evidence are real, and the honest position is that resistance is possible but arises more slowly and less transmissibly than for conventional antibiotics.

The second is the salt-sensitivity critique, which was widely read as having deflated the whole antimicrobial peptide field. What the underlying experiments actually showed is that killing activity measured in low-ionic-strength buffer falls sharply at physiological sodium chloride concentration and in the presence of serum proteins. That is a genuine constraint on systemic use. It is not evidence that the peptide is inert at epithelial surfaces, where local concentrations in inflamed tissue are far higher and where the Kostmann data indicate real biological consequence. The shift in scientific opinion here is best described as a narrowing of the claimed domain rather than a refutation, and the question of how much direct killing LL-37 performs in living human tissue remains open.

Expected Benefits

High 🟩 🟩 🟩

Broad-Spectrum Antimicrobial and Antibiofilm Activity

LL-37 kills gram-positive and gram-negative bacteria, several fungi, and enveloped viruses by physically disrupting their membranes, and at far lower concentrations it prevents biofilm formation by suppressing attachment and quorum-sensing gene expression. The proposed mechanism is electrostatic capture of the peptide by anionic microbial surfaces followed by helix insertion and pore or carpet formation. The evidence base is unusually deep for a non-approved agent: hundreds of independently replicated in vitro susceptibility studies, consistent animal infection models, and human genetic evidence from cathelicidin-deficient Kostmann patients who develop aggressive periodontal disease despite normal neutrophil counts. The important qualification is that this activity is measured largely outside the body: in plasma at physiological salt concentration the peptide is substantially inactivated by binding to apolipoprotein A-I, and the one human wound trial that counted bacteria found no reduction in aerobic colonization on LL-37 (Miranda et al., 2023), so the benefit rests on laboratory and genetic evidence rather than on demonstrated bacterial clearance in treated human tissue.

Magnitude: Minimum inhibitory concentrations (the lowest concentration that stops visible bacterial growth) typically fall between 1 and 32 µg/mL against Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli; biofilm formation is inhibited at roughly 0.5–4 µg/mL, often more than tenfold below the killing concentration.

Medium 🟩 🟩

Accelerated Healing of Hard-to-Heal Skin Ulcers ⚠️ Conflicted

Topical LL-37 applied twice weekly improved healing predictors relative to placebo in the first randomized controlled trial of the peptide in humans, in long-standing venous leg ulcers (Grönberg et al., 2014), and an independent randomized double-blind trial in diabetic foot ulcers later reported the same direction of effect (Miranda et al., 2023). The proposed mechanism combines reduced bacterial burden, keratinocyte migration driven by epidermal growth factor receptor transactivation, and new blood vessel formation. The evidence basis is a 34-participant, first-in-human, dose-ranging trial with a 3-week placebo run-in and 4-week treatment phase — an appropriate but small study conducted and funded by Pergamum AB, the company developing the product, whose employees are among the authors, which is a direct financial interest in a favorable result — together with a 40-participant academic trial that carries no such interest but also reported no reduction in wound cytokines or bacterial counts. The evidence is conflicted, and the conflict is decisive: the same developer then ran a far larger 148-participant multicentre phase IIb trial in the same indication, and it found no significant healing advantage for either concentration over placebo across the full study population, with benefit appearing only in an unplanned analysis of the subgroup with wounds of at least 10 cm² (Mahlapuu et al., 2021). The most plausible reasons for the discrepancy are the small size and healing-predictor endpoints of the first trial against the hard, pre-specified endpoints of the larger one, differences in wound size and duration between the populations, and the fact that the 148-participant trial dropped the 3.2 mg/mL arm that had already failed.

Magnitude: In the 34-participant trial, healing rate constants were approximately sixfold higher than placebo at 0.5 mg/mL (p = 0.003, meaning a result this large would arise by chance about 3 times in 1,000 if the treatment did nothing) and threefold higher at 1.6 mg/mL (p = 0.088); mean ulcer area fell 68% and 50% respectively, while the 3.2 mg/mL group was indistinguishable from placebo. In the diabetic foot ulcer trial the granulation index rose more on LL-37 at days 7, 14, 21 and 28 (p = 0.031, 0.009, 0.006 and 0.037). In the 148-participant phase IIb trial the difference from placebo was not significant at either 0.5 or 1.6 mg/mL.

Increased Endogenous Cathelicidin Production Following Vitamin D Repletion ⚠️ Conflicted

Correcting vitamin D deficiency raises circulating and tissue cathelicidin through the vitamin D response element in the CAMP promoter, offering a route to higher LL-37 that requires no injection. The evidence basis includes a randomized placebo-controlled trial in intensive care patients with severe sepsis in which high-dose cholecalciferol raised plasma LL-37 while placebo lowered it (Quraishi et al., 2015), and a randomized trial plus follow-up cohort in young men in which baseline vitamin D insufficiency was inversely associated with cathelicidin concentration (Laaksi et al., 2024). The evidence is conflicted: several supplementation trials in vitamin D-replete populations found no change in circulating cathelicidin, the same Laaksi trial found no effect of daily supplementation on respiratory infections, and the tuberculosis meta-analysis found high circulating cathelicidin coexisting with low local expression in active disease, indicating that the plasma measurement is not a clean proxy for tissue function.

Magnitude: Median plasma LL-37 rose 30% (interquartile range 23–48%, the span covering the middle half of participants) with 400,000 IU (international units, the standard measure of vitamin D dose) cholecalciferol versus a 17% fall on placebo by day 5 (p = 0.04); baseline vitamin D insufficiency below 50 nmol/L was inversely associated with cathelicidin concentration (odds ratio 0.49 — the odds ratio compares the odds of an outcome between two groups, so values below 1 mean lower odds — with a 95% confidence interval of 0.24–0.99, the range within which the true value is expected to lie).

Low 🟩

Neutralization of Bacterial Endotoxin

LL-37 binds the lipid A portion of bacterial lipopolysaccharide with high affinity and prevents it from engaging toll-like receptor 4, which blunts the downstream cytokine cascade responsible for much of the tissue injury in gram-negative infection. The proposed mechanism is direct stoichiometric sequestration rather than receptor antagonism. The evidence basis is consistent in vitro work in human monocytes and whole blood plus rodent endotoxemia models; the systematic review of host defense peptides in sepsis specifically notes that much of the supporting human-relevant literature used endotoxin challenge rather than genuine infection, which limits what can be concluded (Ho et al., 2017). No trial has tested whether administered LL-37 improves any clinical outcome in human infection.

Magnitude: Lipopolysaccharide-induced tumor necrosis factor alpha release is suppressed by roughly 50–90% at LL-37 concentrations of 1–10 µg/mL in human monocyte assays.

Promotion of Angiogenesis and Re-Epithelialization

Beyond killing microbes, LL-37 recruits endothelial cells and drives new capillary formation through formyl peptide receptor 2, and accelerates keratinocyte migration across a wound bed. The proposed mechanism runs through receptor-mediated signaling rather than membrane disruption, which is why the effective concentrations are far lower than antimicrobial ones. The evidence basis is animal wound models, human keratinocyte and endothelial culture, and the healing-predictor endpoints of the single human ulcer trial; there is no human study isolating angiogenesis as an endpoint. Whether this is a benefit depends on context, since the same activity supports tumor vascularization.

Magnitude: Vessel density roughly doubles in animal wound and chorioallantoic membrane models at LL-37 concentrations around 1–5 µg/mL.

Association Between Higher Circulating Cathelicidin and Lower Infection Mortality

Among adults starting chronic hemodialysis, lower baseline plasma hCAP18 predicted death from infection within one year (Gombart et al., 2009). The proposed mechanism is straightforward — less available antimicrobial peptide means weaker first-line defense — and the finding is biologically coherent with the Kostmann observations. The evidence basis is a case-control study nested in a 10,044-patient prospective cohort, which is a strong observational design but cannot establish causation, and the population is a high-risk dialysis cohort rather than the healthy adults this review addresses. Baseline hCAP18 correlated with 1,25-dihydroxyvitamin D but not with 25-hydroxyvitamin D, which weakens the assumption that vitamin D supplementation is the lever.

Magnitude: The lowest tertile (bottom third) of plasma hCAP18 carried an odds ratio of 2.1 (95% confidence interval 1.2–3.5) for infectious death, rising to 3.7 (95% confidence interval 1.2–11.2) after multivariable adjustment; mean levels were 539 ng/mL in cases versus 650 ng/mL in controls.

Speculative 🟨

Direct Antitumor Activity ⚠️ Conflicted

LL-37 has been proposed to shrink tumors by recruiting and activating plasmacytoid dendritic cells within the tumor, converting an immunologically cold lesion into a hot one. The only human test was a phase 1/2 trial of weekly intratumoral injection in metastatic melanoma at a United States cancer center, which enrolled 4 of a planned 36 participants over five years and reported outcomes on 3 evaluable patients (NCT02225366). No efficacy conclusion can be drawn from that sample. The basis for this claim is therefore mechanistic and anecdotal only, and it is directly conflicted by a substantial body of work showing that LL-37 promotes proliferation and metastasis in cancers of the ovary, lung, breast, prostate, pancreas, and skin while suppressing colon, gastric, and hematologic malignancy (Chen et al., 2018). The direction of effect appears to be decided by which receptor a given tissue expresses, which is not predictable in advance for an individual.

Inhibition of Amyloid Aggregation

LL-37 has been reported to block the self-assembly of islet amyloid polypeptide, the protein whose aggregation accompanies pancreatic islet failure in type 2 diabetes, at nanomolar concentrations in cell-free systems. The proposed mechanism is direct binding to aggregation-prone intermediates. No controlled study in animals or humans has tested whether this translates into preserved islet function or any clinical endpoint, so the basis is entirely mechanistic in vitro work.

Support of Healthspan Through Innate Immune Resilience

The broader proposition motivating longevity interest is that maintaining robust endogenous antimicrobial peptide capacity preserves barrier integrity, limits chronic low-grade microbial stimulation, and thereby slows inflammatory aging. No controlled study has examined LL-37 status against any aging, frailty, or mortality endpoint in a general adult population, and the one mortality dataset available comes from dialysis patients. The basis is mechanistic reasoning extrapolated from infection biology, with no direct supporting data.

Benefit-Modifying Factors

  • Vitamin D receptor and vitamin D pathway polymorphisms: Common variants in VDR (FokI, BsmI, TaqI) alter receptor abundance and transcriptional efficiency, and variants in CYP27B1 (the enzyme that activates vitamin D) and CYP24A1 (the enzyme that degrades it) shift how much active hormone reaches the CAMP promoter. Two people with identical 25-hydroxyvitamin D levels can therefore mount different cathelicidin responses to the same supplement dose.
  • Vitamin D binding protein genotype: Variants in GC (the gene encoding vitamin D binding protein, the carrier that holds most circulating vitamin D) determine how much of circulating vitamin D is bioavailable rather than protein-bound. In the sepsis trial, cathelicidin rose in step with bioavailable 25-hydroxyvitamin D but not with total 25-hydroxyvitamin D, making this genotype a plausible determinant of who responds to the endogenous-induction route.
  • Cathelicidin gene promoter variation: Polymorphisms in the CAMP promoter region influence baseline expression and vitamin D responsiveness, and would be expected to set the ceiling on what any induction strategy can achieve.
  • Baseline vitamin D status: The induction benefit is concentrated in deficiency. Trials in vitamin D-replete participants have generally found no increase in circulating cathelicidin, whereas trials starting from insufficiency have. Baseline 25-hydroxyvitamin D below 20 ng/mL identifies those with headroom; above roughly 40 ng/mL, additional supplementation is unlikely to raise the peptide further.
  • Baseline cathelicidin concentration: Because the dose-response of exogenous LL-37 is inverted rather than monotonic — the highest dose in the leg ulcer trial performed no better than placebo — someone whose tissue cathelicidin is already elevated by inflammation stands to gain less and risk more than someone starting low.
  • Sex-based differences: Circulating hCAP18 tends to run modestly higher in women in general population cohorts, and estrogen upregulates CAMP expression in reproductive tract epithelium. Women also carry the higher prevalence of the conditions in which cathelicidin is already excessive — rosacea and lupus — which shifts the expected net benefit downward for women with those phenotypes and leaves it unchanged for those without.
  • Pre-existing health conditions: Wound healing benefit is most plausible where healing is impaired but perfusion is adequate. Conditions that raise baseline cathelicidin — psoriasis, rosacea, active inflammatory bowel disease, chronic alcohol exposure — reduce or invert the expected benefit. Chronic kidney disease and obesity both lower bioavailable vitamin D and may enlarge the induction benefit. Severe atopic dermatitis is the notable exception in the opposite direction: it features abnormally low skin cathelicidin, which is the mechanistic basis for its characteristic staphylococcal colonization.
  • Age-related considerations: Skin loses roughly 75% of its capacity to synthesize vitamin D between ages 20 and 70, and neutrophil granule content and epithelial cathelicidin expression both decline with age. Adults in the upper half of the target range therefore have the most room for the induction route to matter, while simultaneously carrying more accumulated arterial disease, which raises the cost of the peptide’s effect on cholesterol handling in plaque macrophages.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Local Skin and Injection-Site Reactions

Injected LL-37 produces reactions at the site of contact in humans, ranging from erythema (redness) and stinging to bullous (blistering) and verrucous (warty) lesions, whereas the topical route has so far been tolerated without reported local toxicity. The mechanism is the peptide’s own alarmin activity: it recruits neutrophils and mast cells and induces interleukin-36 gamma in keratinocytes, so local inflammation is an on-target effect rather than an impurity effect. The evidence basis is the melanoma trial’s posted results, in which all 3 evaluable participants experienced non-serious adverse events including squamous cell carcinoma, actinic keratosis (a rough precancerous patch on sun-damaged skin), and skin hypopigmentation, together with a detailed case report of a woman who developed multiple verrucous papules and a blistering lesion across trunk and limbs about 45 days into weekly injections, with 11 of 12 biopsies showing lichenoid inflammation (a dense band of immune cells attacking the base of the epidermis) and atypical squamous proliferation (Dolkar et al., 2018). The reassuring feature is reversibility: all lesions resolved within two months of stopping.

Magnitude: 3 of 3 evaluable participants (100%) in the melanoma trial had at least one adverse event; the trial protocol pre-specified grade 3 injection-site skin reactions as expected and excluded them from the dose-limiting toxicity definition. The topical leg ulcer trial reported no local or systemic safety concerns at 0.5–3.2 mg/mL.

Loss of Benefit and Cytotoxicity at Higher Concentrations

LL-37 has an inverted dose-response, and above a threshold it damages the tissue it was applied to protect. The mechanism is loss of membrane selectivity: at high concentration the amphipathic helix inserts into cholesterol-containing mammalian membranes as well as microbial ones, lysing keratinocytes, fibroblasts, and red blood cells. The evidence basis is the human dose-ranging trial, in which the highest dose tested performed no better than placebo, combined with consistent in vitro cytotoxicity thresholds across many independent laboratories. This is the single most practically important risk for anyone self-administering, because the intuition that more peptide means more effect is exactly wrong here.

Magnitude: 3.2 mg/mL topical gel produced no healing advantage over placebo while 0.5 mg/mL produced a roughly sixfold higher healing rate constant; cytotoxicity to human keratinocytes and fibroblasts appears above approximately 25–50 µM and hemolysis above approximately 100 µM.

Medium 🟥 🟥

Triggering or Worsening of Psoriasis

LL-37 is not merely elevated in psoriatic skin, it is a target of the autoimmune response that sustains the disease. The mechanism is twofold: LL-37 complexes with a person’s own DNA and RNA to break tolerance in plasmacytoid dendritic cells and drive type I interferon production, and the peptide itself is presented to T cells as an autoantigen. The evidence basis is strong human immunology — two-thirds of patients with moderate-to-severe plaque psoriasis harbor LL-37-specific CD4 or CD8 T cells (the helper and killer subsets of the immune system’s memory cells) producing interferon gamma and T-helper-17 cytokines, and the presence of circulating LL-37-specific T cells correlates with disease activity (Lande et al., 2014). Administering additional peptide to someone with this immune repertoire supplies more of the antigen driving their disease.

Magnitude: Approximately 67% of patients with moderate-to-severe plaque psoriasis carry LL-37-specific T cells; psoriasis affects 2–3% of the population, so a meaningful fraction of any adult cohort is affected.

Triggering or Worsening of Rosacea

People with rosacea express abnormally high levels of cathelicidin and, more importantly, abnormally processed fragments generated by excess stratum corneum tryptic enzyme activity in the epidermis. The mechanism is that these specific fragments, not the intact peptide, are the inflammatory drivers. The evidence basis is direct and causal in animals with strong human correlative support: injecting the rosacea-type cathelicidin peptides into mouse skin produces inflammation, adding the processing enzyme increases it, deleting the cathelicidin gene abolishes it (Yamasaki et al., 2007), and a systematic review of 119 rosacea biomarkers found the cathelicidin and inflammasome pathway among the best supported (Geng et al., 2024). Since applied LL-37 enters the same skin protease environment, the processing abnormality is not bypassed by supplying the intact peptide.

Magnitude: Rosacea affects approximately 3% of adults over 30; the erythematotelangiectatic subtype (persistent facial redness with visible small blood vessels) accounts for about 57% of cases and the papulopustular subtype (redness with acne-like bumps and pus-filled spots) about 43%.

Mast Cell Degranulation and Pseudo-Allergic Reactions

LL-37 is a direct agonist of MRGPRX2 (Mas-related G protein-coupled receptor X2, a mast cell receptor that triggers histamine release without involving allergy antibodies), producing flushing, wheal-and-flare reactions (a raised welt ringed by redness), itching, and in principle hypotension (a drop in blood pressure below the normal range) without any prior sensitization. The mechanism explains why reactions can occur on first exposure and why they do not require an allergic history. The evidence basis is human mast cell pharmacology, mouse models of cathelicidin-driven skin inflammation in which mast cells are the required intermediary, and animal work showing that MRGPRX2 antagonism suppresses LL-37-induced rosacea-like inflammation. The severity is usually mild and self-limited, but people with mast cell activation disorders or chronic urticaria (long-standing hives) sit at the reactive end of the distribution.

Magnitude: Not quantified in available studies.

Low 🟥

Acceleration of Atherosclerosis

LL-37 drives cholesterol into the macrophages that become the foam cells of arterial plaque. The mechanism is specific and well mapped: LL-37 forms a complex with low-density lipoprotein (LDL, the cholesterol-carrying particle that deposits in artery walls) that is taken up through the LDL receptor, scavenger receptor class B member 1, and CD36 (a surface protein that macrophages use to take up fats), raising cytosolic cholesterol. The evidence basis is a mechanistic study combining structural work, genetically modified mice expressing human LL-37 that developed larger atherosclerotic plaques, and a positive correlation between plasma LL-37 and oxidized phospholipid on apolipoprotein B in people with cardiovascular disease (Nakamura et al., 2024). The finding is graded Low only because no prospective human outcome data exist; its most striking feature is that the effect is unique to human and some primate cathelicidins and absent for the mouse and rabbit versions, meaning most prior animal safety work could not have detected it.

Magnitude: Not quantified in available studies.

Tumor Promotion in Susceptible Tissues ⚠️ Conflicted

LL-37 is overexpressed in and promotes proliferation, migration, and metastasis in cancers of the ovary, lung, breast, prostate, pancreas, and skin, while inhibiting colon cancer, gastric cancer, and some hematologic malignancies. The mechanism is receptor-dependent: the same peptide engages different surface receptors and downstream pathways in different tissues, producing opposite outcomes. The evidence basis is a large body of cell and animal work summarized in a dedicated review (Chen et al., 2018), plus the United States Food and Drug Administration’s explicit statement that nonclinical findings indicate cathelicidin LL-37 can be protumorigenic in some tissues (Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks). The evidence is genuinely conflicted, and because the direction depends on tissue receptor expression, an individual cannot know in advance which way it would run for them.

Magnitude: Not quantified in available studies.

Contribution to Systemic Autoimmunity

Beyond psoriasis, LL-37 is a component of neutrophil extracellular traps and a target of autoantibodies in systemic lupus erythematosus (a disease in which the immune system attacks multiple organs), psoriatic arthritis, and rheumatoid arthritis, particularly after post-translational modification such as citrullination. The mechanism is the same DNA- and RNA-chaperone activity that operates in skin, exported to the circulation via neutrophil extracellular traps, plus generation of neo-epitopes by protein modification. The evidence basis is human autoantibody and T-cell studies across several rheumatic diseases and a body of work on the peptide’s role in trap formation (Radic & Muller, 2022). No prospective study has tested whether administering LL-37 induces autoimmunity in a person who does not already have it.

Magnitude: Not quantified in available studies.

Adverse Effects on Male Reproductive Function

The United States Food and Drug Administration stated, in placing cathelicidin LL-37 in the safety-risk category of its compounding bulk substances review, that nonclinical research findings suggest detrimental effects on male reproduction. The plausible mechanism is the peptide’s membrane-lytic activity acting on sperm, whose membranes are unusually susceptible, consistent with reported spermicidal activity of LL-37 at higher concentrations. The evidence basis is preclinical only, and the agency did not publish the underlying dataset. The finding is noted here because it is a regulator’s stated safety concern about this specific substance rather than a general peptide caution, and because it is absent from most promotional material.

Magnitude: Not quantified in available studies.

Speculative 🟨

Systemic Toxicity From Injected or Nebulized Peptide

Subcutaneous, intravenous, and inhaled routes are used in the peptide market but have never been studied in humans for LL-37. The concern is that concentrations achieving any systemic effect would approach the hemolytic and cytotoxic range, and that a peptide whose function is to summon neutrophils could provoke systemic inflammation. No controlled human data exist for any systemic route; the basis is mechanistic reasoning and isolated rodent reports of hypotension and hemolysis at high intravenous doses.

Immunogenicity Against the Body’s Own Peptide

Repeated injection of a synthetic copy of an endogenous human peptide, particularly one prone to aggregation and carrying synthesis-related impurities, could raise antibodies that cross-react with the person’s own cathelicidin and impair innate defense. This is the primary theoretical concern the United States Food and Drug Administration named in its review. There are no human immunogenicity data for LL-37 at all, so the basis is regulatory reasoning by analogy with other peptides rather than observed cases.

Harm From Contaminants in Unregulated Product

Research-grade peptides are not manufactured to pharmaceutical quality standards, and endotoxin, residual synthesis solvents, truncated sequences, and outright substitution are documented problems in this market generally. For LL-37 specifically, endotoxin contamination is a particular concern because the peptide binds endotoxin, which could alter both the impurity’s behavior and the peptide’s activity in unpredictable ways. No testing survey of commercially sold LL-37 has been published, so the basis is extrapolation from the wider research-peptide market rather than direct measurement.

Risk-Modifying Factors

  • HLA-C*06:02 (human leukocyte antigen, the cell-surface system that presents fragments of proteins to T cells) and psoriasis-associated immune genotype: The T-cell response to LL-37 in psoriasis is restricted by particular HLA types, with HLA-C*06:02 the best-characterized psoriasis risk allele. Carriers who already have or are predisposed to psoriasis represent the group most likely to convert supplied peptide into an autoimmune stimulus.
  • Kallikrein and protease inhibitor pathway variation: Variants affecting KLK5 (kallikrein-related peptidase 5) activity or SPINK5 (the gene encoding the protein that restrains that enzyme) determine how skin processes cathelicidin. Loss of that restraint generates the abnormal fragments implicated in rosacea, meaning identical applied peptide yields different products in different people.
  • MRGPRX2 variation and mast cell burden: Functional variants in the mast cell receptor LL-37 activates, and conditions with expanded mast cell populations such as systemic mastocytosis (an excess of mast cells throughout the body) or chronic spontaneous urticaria, raise the probability and severity of flushing, itching, and wheal reactions.
  • Baseline cathelicidin and inflammatory biomarkers: Elevated baseline plasma LL-37 or high-sensitivity C-reactive protein indicates that the endogenous system is already running hot; adding peptide in that setting shifts the expected balance toward the inflammatory and autoimmune risks and away from the antimicrobial benefit. Elevated lipoprotein(a) or apolipoprotein B compounds the atherosclerosis concern, since the peptide’s plaque effect operates by loading macrophages with the very particles those markers count.
  • Sex-based differences: Women carry three to four times the prevalence of rosacea and roughly nine times the prevalence of systemic lupus erythematosus, both conditions in which excess or modified cathelicidin is mechanistically implicated, so the autoimmune and cutaneous risk profile is materially higher in women. The reproductive toxicity signal the regulator identified is specific to males. Sex therefore shifts which risks dominate rather than the overall level.
  • Pre-existing health conditions: Psoriasis, psoriatic arthritis, rosacea, systemic lupus erythematosus, and rheumatoid arthritis with anti-citrullinated protein antibodies all sit directly on the peptide’s autoimmune mechanism. Established atherosclerotic disease sits on the lipid-handling mechanism. A history of ovarian, lung, breast, prostate, pancreatic, or skin malignancy sits on the tumor-promotion mechanism. Severe atopic dermatitis is the one condition in which low cathelicidin is the abnormality, which changes the risk calculus in the opposite direction.
  • Age-related considerations: Older adults carry more subclinical atherosclerosis, a higher lifetime probability of an occult epithelial malignancy, and slower resolution of cutaneous inflammation, all of which magnify the consequences of the peptide’s off-target effects. Actinic keratosis and squamous cell carcinoma appeared among the adverse events in the melanoma trial, and photodamaged older skin already carries the field change from which those lesions arise.

Key Interactions & Contraindications

Cathelicidin LL-37 is a peptide cleared by proteolysis rather than by liver enzymes, so it has no cytochrome P450-mediated drug interactions. Its interactions are pharmacodynamic — agents that raise or lower endogenous cathelicidin, and agents whose activity depends on the same charged surfaces the peptide binds.

  • Systemic and topical corticosteroids (prednisone, dexamethasone, hydrocortisone, clobetasol propionate, fluticasone): Glucocorticoids suppress CAMP transcription and lower cathelicidin in skin and blood. Severity: interaction, monitor. Consequence: antagonism of any induction strategy and a plausible mechanistic contributor to the increased skin and soft tissue infection rates seen on chronic steroid therapy. Mitigation: when corticosteroid therapy cannot be avoided, the induction route should be expected to underperform, and dose reduction rather than added peptide is the lever that actually restores expression.
  • Systemic retinoids (isotretinoin, acitretin) and high-dose vitamin A: Retinoic acid suppresses vitamin D-driven CAMP induction while simultaneously increasing kallikrein expression, which alters the balance between intact peptide and inflammatory fragments. Severity: caution. Consequence: unpredictable net change in active cathelicidin species in skin. Mitigation: separating the two interventions in time rather than combining them, and avoiding preformed vitamin A above 3,000 µg retinol activity equivalents daily during a vitamin D induction attempt.
  • Heparin and heparin-like anticoagulants (unfractionated heparin, enoxaparin, dalteparin, fondaparinux, danaparoid): LL-37 is strongly cationic and binds heparin and other sulfated glycosaminoglycans with high affinity, mirroring the mechanism by which protamine reverses heparin. Severity: caution. Consequence: theoretical partial neutralization of anticoagulant effect with systemic exposure, and conversely, sequestration of the peptide. Mitigation: no systemic co-administration; if unavoidable, anticoagulation monitoring rather than dose assumption.
  • Antibiotics acting on the bacterial envelope (aminoglycosides such as gentamicin, polymyxins such as colistin, glycopeptides such as vancomycin, beta-lactams such as amoxicillin): LL-37 permeabilizes the outer membrane and is broadly synergistic with these agents in vitro. Severity: interaction, generally favorable but unquantified in humans. Consequence: greater than additive killing, with a theoretical increase in the rate of bacterial lysis and endotoxin release. Mitigation: none established; the synergy has not been tested clinically.
  • Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin): These agents suppress prostaglandin-driven inflammation without acting on CAMP transcription, so they neither raise nor lower the peptide but do mask the local inflammatory response that would otherwise signal an excessive dose. Severity: caution. Consequence: delayed recognition of application-site toxicity. Mitigation: avoiding routine pre-emptive use around application.
  • Over-the-counter antihistamines (cetirizine, fexofenadine, diphenhydramine): These block the histamine released when LL-37 activates mast cell receptors. Severity: interaction, mitigating. Consequence: attenuation of flushing, itching, and wheal reactions. Mitigation: their effectiveness here masks rather than removes the underlying degranulation.
  • Vitamin D3 (cholecalciferol) and calcitriol: The single strongest additive interaction. These act on the same vitamin D response element that drives CAMP, so they raise endogenous cathelicidin on top of any supplied peptide. Severity: additive, monitor. Consequence: compounded exposure in someone already predisposed to the peptide’s inflammatory effects, plus the independent risk of hypercalcemia (too much calcium in the blood) at high doses. Mitigation: serum calcium and 25-hydroxyvitamin D measurement before and during high-dose use, with 25-hydroxyvitamin D kept below 80 ng/mL.
  • Butyrate, tributyrin, and sodium phenylbutyrate: These histone deacetylase inhibitors induce CAMP through a vitamin D-independent route and are additive with vitamin D. Severity: additive. Consequence: further elevation of endogenous peptide. Mitigation: the same caution applied to vitamin D, since the endpoint is identical.
  • Nicotinamide, curcumin, and sulforaphane: Each has been reported to induce cathelicidin expression in keratinocytes or myeloid cells, making them lower-magnitude additive agents. Severity: additive, minor. Consequence: incremental increase in endogenous peptide. Mitigation: none required at ordinary supplement doses; relevant mainly to people stacking multiple inducers.
  • Omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid): Being tested as a modifier of hCAP18 alongside vitamin D in a large randomized trial, with results not yet reported. Severity: unknown. Consequence: undetermined. Mitigation: none; the interaction is under active investigation.

Populations in which use should be avoided:

  • Moderate-to-severe plaque psoriasis, defined as a Psoriasis Area and Severity Index score of 10 or above or 10% or more body surface area involvement, and any psoriasis with active plaques — absolute contraindication on the basis of the T-cell autoantigen mechanism.
  • Papulopustular or erythematotelangiectatic rosacea of any severity — absolute contraindication on the basis of the abnormal cathelicidin processing mechanism.
  • Systemic lupus erythematosus meeting 2019 European Alliance of Associations for Rheumatology and American College of Rheumatology classification criteria, psoriatic arthritis, or seropositive rheumatoid arthritis with anti-citrullinated protein antibodies — absolute contraindication.
  • Active malignancy, or treated malignancy of the ovary, lung, breast, prostate, pancreas, or skin within 5 years of documented disease-free status — absolute contraindication.
  • Established atherosclerotic cardiovascular disease, including prior myocardial infarction or stroke, coronary artery calcium score above 100 Agatston units, or lipoprotein(a) above 125 nmol/L — avoid.
  • Systemic mastocytosis, chronic spontaneous urticaria, or documented mast cell activation syndrome — avoid.
  • Pregnancy and lactation — avoid; no human reproductive safety data exist and the regulator has flagged a preclinical reproductive signal.
  • Men currently attempting conception — avoid, on the basis of the stated preclinical male reproductive findings.
  • Severe congenital neutropenia, chronic granulomatous disease (an inherited condition in which white blood cells cannot produce the burst of reactive oxygen they need to kill swallowed microbes), or other primary immunodeficiency — avoid outside specialist supervision, since these are precisely the settings where the endogenous system is abnormal and the consequences of perturbing it are unpredictable.

Risk Mitigation Strategies

  • Screening for the autoimmune and inflammatory contraindications before any use: A dermatological and rheumatological history covering psoriasis, rosacea, lupus, psoriatic arthritis, and seropositive rheumatoid arthritis, supplemented where the history is ambiguous by antinuclear antibody testing at a 1:80 titre cutoff and anti-citrullinated protein antibody measurement. This directly addresses the peptide’s best-documented serious risk, which is amplification of an existing autoimmune process against LL-37 itself.
  • Starting at the low end of the demonstrated dose-response and not escalating: The only human dose-ranging data show 0.5 mg/mL topical outperforming 1.6 mg/mL, with 3.2 mg/mL indistinguishable from placebo. Beginning at 0.5 mg/mL and treating a lack of response as a reason to stop rather than to increase prevents the cytotoxicity and loss-of-efficacy that define the upper end of the curve.
  • Restricting exposure to topical and localized routes: Confining use to intact-bordered skin lesions or defined wound beds keeps concentrations local, avoids the plasma compartment where apolipoprotein A-I binding inactivates the peptide anyway, and sidesteps the entirely uncharacterized systemic pharmacokinetics. This mitigates systemic immunogenicity, hypotension, and hemolysis risk.
  • Patch testing a small area before broader application: Applying the intended concentration to a 2 cm × 2 cm area of comparable skin and observing for 72 hours identifies the mast cell-mediated flushing and wheal reactions and the lichenoid reaction pattern before a larger surface is committed.
  • Capping duration and imposing scheduled stops: The human trial applied gel twice weekly for 4 weeks; the melanoma trial injected weekly for 8 weeks; the case of severe cutaneous toxicity appeared at day 45. Limiting any single course to 4 weeks with a mandatory stop mitigates the cumulative cutaneous reactions, which resolved within two months of cessation in the reported case.
  • Baseline and interval cardiovascular lipid assessment: Measuring apolipoprotein B and lipoprotein(a) before starting and at 12 weeks addresses the atherosclerosis mechanism, in which LL-37 loads plaque macrophages with low-density lipoprotein. Deferring use where apolipoprotein B exceeds 80 mg/dL or lipoprotein(a) exceeds 125 nmol/L removes those with the most to lose from that specific pathway.
  • Full-body skin examination before and after a course: Because squamous cell carcinoma and actinic keratosis appeared among adverse events and the regulator has flagged tumor promotion, dermatological examination before starting and again at 3 months detects new lesions while they are small and reversible, and separates pre-existing photodamage from new events.
  • Choosing the endogenous induction route in preference to exogenous peptide where the goal is antimicrobial capacity: Raising 25-hydroxyvitamin D from deficiency to 40–50 ng/mL with 2,000–5,000 IU cholecalciferol daily, with serum calcium checked at 12 weeks, achieves cathelicidin elevation through a route with decades of safety data. This mitigates every risk unique to the injected or applied synthetic peptide — immunogenicity, contaminants, local toxicity, and unknown systemic behavior.
  • Sourcing verification with independent analysis: Requiring a certificate of analysis showing purity above 98% by high-performance liquid chromatography, mass spectrometric confirmation of the correct 4,493 dalton mass, and endotoxin below 1 endotoxin unit per milligram addresses the contaminant risk that the absence of pharmaceutical manufacturing standards creates.
  • Antihistamine availability during initial exposures: Having a second-generation antihistamine on hand for the first several applications mitigates the mast cell degranulation reaction, which can occur on first exposure because it does not require prior sensitization.

Therapeutic Protocol

No approved protocol for cathelicidin LL-37 exists in any jurisdiction, and no clinic or professional body publishes a standard regimen. What follows is the documented human dosing from the trials that have been conducted, alongside the endogenous-induction alternative, presented so that the evidentiary basis of each is explicit.

  • Topical protocol from the venous leg ulcer trial: LL-37 in a hydrogel at 0.5 mg/mL applied twice weekly to a debrided ulcer bed for 4 weeks, after a 3-week vehicle-only run-in to establish the healing baseline. This is the most-tested regimen, though the same 0.5 mg/mL concentration failed to beat placebo when carried into a 148-participant phase IIb trial in the same indication (Mahlapuu et al., 2021). It was developed by Pergamum AB and Lipopeptide AB in Sweden in collaboration with Mona Ståhle at the Karolinska Institute and Ola Rollman at Uppsala; the sponsoring company had a direct commercial interest in the outcome.
  • Topical protocol from the diabetic foot ulcer trial: LL-37 cream at 0.5 mg/mL applied twice weekly for 4 weeks alongside standard wound care, tested in 40 patients at the Faculty of Medicine, Universitas Indonesia (NCT04098562). Its results were published in 2023 and showed a consistently greater rise in granulation index on LL-37 without any fall in wound interleukin-1 alpha, tumor necrosis factor alpha, or aerobic bacterial counts (Miranda et al., 2023), which makes this the one regimen carrying independent, non-commercial randomized support.
  • Intratumoral protocol from the melanoma trial: 250 µg per tumor injected into 2–4 cutaneous or subcutaneous lesions once weekly for up to 8 weeks, escalating to 500 µg per tumor in the second cohort, conducted by Rodabe Amaria at the University of Texas MD Anderson Cancer Center (NCT02225366). Only 3 participants were evaluable across both dose levels, so this establishes the doses that have been given to humans but not that they are effective or safe at scale.
  • Endogenous induction through vitamin D: Cholecalciferol 2,000–5,000 IU daily titrated to a 25-hydroxyvitamin D of 40–50 ng/mL is the approach with the deepest safety record. The intensive care trial that demonstrated a cathelicidin rise used a single 400,000 IU loading dose, which is a research dose and not a maintenance regimen. This route traces to the work of Adrian Gombart at Oregon State University and Philip Koeffler, who identified the vitamin D response element in the gene.
  • Endogenous induction through histone deacetylase inhibition: Sodium phenylbutyrate 500 mg twice daily combined with cholecalciferol 5,000 IU daily for 8 weeks is the regimen tested in pulmonary tuberculosis by the International Centre for Diarrhoeal Disease Research, Bangladesh, in collaboration with Peter Bergman, Birgitta Agerberth, and Rubhana Raqib (NCT01580007). The dietary analogue is butyrate or tributyrin at 300–600 mg daily, or fermentable fiber sufficient to raise colonic short-chain fatty acid production, neither of which has been tested against a cathelicidin endpoint.
  • Peptide-market practice: Subcutaneous injection of 100–300 µg daily and nebulized administration are described in vendor material and user communities. These have no trial basis, no pharmacokinetic characterization, and no safety data, and they use routes the only human trials deliberately avoided. They are recorded here because they are what is actually being done, not because evidence supports them.
  • Timing of administration: Cathelicidin expression follows the circadian rhythm of neutrophil trafficking, with neutrophil counts and granule release peaking in the evening in day-active people. Topical protocols in trials specified twice-weekly application without time-of-day constraints. Vitamin D induction is best served by taking cholecalciferol with the largest fat-containing meal of the day, which improves absorption by roughly 30–50%; time of day beyond that has no established effect on the cathelicidin endpoint.
  • Half-life considerations: The plasma half-life of administered LL-37 in humans has never been measured. Synthetic peptide is fully degraded by trypsin within 6 hours in vitro yet resists chronic wound fluid for at least 24 hours, which is why topical dosing intervals of 3–4 days proved adequate while any systemic route would face far faster clearance. Cholecalciferol, by contrast, has a circulating half-life of 2–3 weeks as 25-hydroxyvitamin D, which is why daily rather than intermittent dosing produces the steadiest substrate for gene induction.
  • Single versus split dosing: All human LL-37 protocols used single applications or injections per session rather than divided doses, and the inverted dose-response argues against attempting to reach a higher total by splitting. For the vitamin D route, daily dosing produces more stable 25-hydroxyvitamin D and better cathelicidin induction than weekly or monthly bolus regimens, which produce peaks and troughs in the active hormone.
  • Genetic considerations in protocol selection: VDR FokI and BsmI genotype, GC genotype determining vitamin D binding protein, and CYP24A1 variants each shift how much cholecalciferol is required to reach a given active hormone concentration, so the induction route benefits from titrating to measured 25-hydroxyvitamin D rather than to a fixed dose. SPINK5 and kallikrein pathway variation determines how applied peptide is processed in skin and argues for a conservative topical concentration in anyone with a family history of rosacea or Netherton syndrome (a rare inherited disorder in which loss of that same protease restraint leaves the skin barrier defective).
  • Sex-based considerations in protocol selection: No human study has stratified LL-37 dosing by sex. The higher female prevalence of rosacea and lupus argues for lower topical concentrations and shorter courses in women with any cutaneous or autoimmune history, while the preclinical male reproductive signal argues against use in men attempting conception at any dose.
  • Age-related considerations in protocol selection: Older adults require more cholecalciferol to reach the same 25-hydroxyvitamin D because of reduced cutaneous synthesis and altered body composition, typically at the upper end of the 2,000–5,000 IU range. For topical use, thinner and more photodamaged skin in the upper part of the target age range argues for the 0.5 mg/mL concentration and against any escalation.
  • Baseline biomarkers influencing response: Baseline 25-hydroxyvitamin D below 20 ng/mL predicts a cathelicidin response to supplementation; above 40 ng/mL it generally does not. Baseline bioavailable rather than total 25-hydroxyvitamin D correlated with the LL-37 rise in the sepsis trial, making vitamin D binding protein status a relevant input. Elevated baseline plasma LL-37 or high-sensitivity C-reactive protein indicates the system is already stimulated.
  • Pre-existing conditions influencing response: Chronic kidney disease, obesity, and malabsorption all lower attainable 25-hydroxyvitamin D for a given dose and shift the induction route toward higher requirements. Impaired arterial perfusion limits any topical wound benefit regardless of peptide concentration, since the trial population had venous rather than arterial insufficiency.

Discontinuation & Cycling

  • Intended duration of use: Cathelicidin LL-37 has only ever been studied as a short, defined course — 4 weeks topically, up to 8 weeks intratumorally. Nothing supports continuous or lifelong administration, and the peptide’s role as an inflammatory alarmin argues against sustained elevation. The endogenous induction route through vitamin D is, by contrast, a maintenance strategy that would ordinarily continue indefinitely, since it restores a physiological set point rather than exceeding one.
  • Withdrawal effects: None have been reported. LL-37 does not act on a receptor system that downregulates in response to occupancy in the way opioid or adrenergic systems do, and no rebound in infection rates or wound deterioration was described after either human trial ended. Abrupt cessation is what was done in the case of severe cutaneous toxicity, and it produced full resolution within two months.
  • Tapering: No tapering protocol exists and none appears necessary. Both trials stopped administration abruptly at the end of the treatment window with no reported consequence, and the biological rationale for tapering — receptor downregulation or physiological dependence — does not apply here.
  • Cycling for maintained efficacy: No evidence addresses whether tolerance develops or whether cycling preserves effect. What the human data do show is the opposite concern: a 45-day continuous course produced a florid cutaneous reaction, and the highest topical dose lost all benefit, so scheduled off-periods are better justified as a toxicity limit than as an efficacy maintenance strategy. A conservative interpretation of the available evidence would confine use to discrete 4-week courses separated by intervals long enough for full cutaneous resolution.
  • Discontinuation triggers: The events that ended treatment in the documented human experience were progressive disease, intolerable local reactions, and new cutaneous lesions. Persistent application-site inflammation beyond 72 hours, any new verrucous or blistering lesion, and any new inflammatory arthralgia (joint pain) or rash suggestive of an autoimmune response are the specific signals that preceded harm in the reported cases.

Sourcing and Quality

  • Regulatory supply status: No pharmaceutical-grade cathelicidin LL-37 is available for human use anywhere. There is no approved product, no outsourcing facility supply, and — following the United States Food and Drug Administration’s review, in which cathelicidin LL-37 was placed among substances presenting significant safety risks before the nomination was withdrawn — no established route for a compounding pharmacy to supply it lawfully in the United States. Every commercially obtainable source is a research-chemical supplier selling material explicitly labeled as not for human consumption.
  • Purity and identity documentation: A meaningful certificate of analysis states purity above 98% by high-performance liquid chromatography, confirms the molecular mass of approximately 4,493 daltons by mass spectrometry, and identifies the counterion, usually trifluoroacetate or acetate. Trifluoroacetate salt is the default output of standard peptide synthesis and is itself cytotoxic at high residual levels; acetate-exchanged material is preferable where available. Certificates supplied by the vendor rather than by an independent laboratory carry no verification value.
  • Endotoxin specification: Because LL-37 binds bacterial endotoxin directly, endotoxin contamination is more than an ordinary sterility issue — it can neutralize peptide activity and confound any response. A specification below 1 endotoxin unit per milligram, tested by limulus amebocyte lysate assay, is the relevant threshold; most research-grade material carries no endotoxin data at all.
  • Formulation and stability: LL-37 is supplied freeze-dried and is stable at −20 °C for months in that form. Once reconstituted, it should be held at 2–8 °C and used within days, since it is a protease substrate and adsorbs to glass and plastic surfaces at low concentrations. Bacteriostatic water containing benzyl alcohol is the usual reconstitution vehicle; plain sterile water offers no preservation. Repeated freeze-thaw cycles promote the aggregation that underlies the immunogenicity concern regulators identified.
  • Reputable sources: No compounding pharmacy or supplement brand can be identified as a reputable source for this peptide, because none supplies it under pharmaceutical quality standards for human use. The research-peptide suppliers that publish third-party mass spectrometry and high-performance liquid chromatography data for each lot are less unreliable than those that do not, but this is a difference of degree within an unregulated market rather than an assurance of quality. For the endogenous induction route, cholecalciferol and sodium phenylbutyrate are both available as tested pharmaceutical or third-party-verified supplement products, which is a substantive quality advantage independent of any efficacy comparison.
  • Counterfeiting and substitution: Peptides sold in this market have been documented to contain incorrect sequences, lower-cost substitutes, or substantially less material than labeled. LL-37 is a comparatively long and expensive 37-residue synthesis, which increases the economic incentive to underfill or substitute. Independent third-party mass spectrometry of a purchased lot is the only practical verification available to a buyer.

Practical Considerations

  • Time to effect: In the venous leg ulcer trial, separation from placebo in healing rate emerged over the 4-week treatment phase, with wound area reductions of 50–68% measured at its end, so several weeks is the realistic interval for a topical wound endpoint. Local reactions appear far sooner — within hours to days — and the serious cutaneous toxicity in the melanoma case report emerged at approximately 45 days. For the endogenous induction route, 25-hydroxyvitamin D takes 8–12 weeks to plateau on a fixed daily dose, and the cathelicidin rise in the intensive care trial was measurable by day 5 after a single very large loading dose.
  • Common pitfalls: The most consequential error is dose escalation, since the human dose-response is inverted and the highest concentration tested performed no better than placebo. The second is choosing systemic routes, which the trials avoided and for which no human data exist, and which run directly into apolipoprotein A-I sequestration in plasma. The third is failing to screen for psoriasis, rosacea, and lupus, in which the peptide is not a neutral addition but the antigen or effector driving the disease. The fourth is treating plasma LL-37 as a target to maximize, when the tuberculosis meta-analysis found high circulating levels alongside low tissue expression in active disease. The fifth is reconstituting a whole vial and storing it for weeks, which promotes the aggregation underlying the immunogenicity concern.
  • Regulatory status: Cathelicidin LL-37 is not approved by the United States Food and Drug Administration or any comparable authority for any indication. It was added to the agency’s list of bulk substances presenting significant safety risks on 29 September 2023, with the stated concerns being immunogenicity risk for certain routes, complexity of impurity and active ingredient characterization, insufficient safety information to know whether it would cause harm in humans, and nonclinical findings suggesting detrimental effects on male reproduction and tumor promotion in some tissues. The nomination was subsequently withdrawn, which removes it from the active category listing without resolving any of those concerns (Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks). All use is therefore outside any regulated pathway.
  • Cost and accessibility: Research-grade LL-37 typically costs roughly USD 40–120 for a 5 mg vial, which places a single topical or injection course in the low hundreds of dollars — not prohibitive by peptide-market standards. Accessibility is nonetheless constrained in a way cost does not capture: no physician can lawfully prescribe it, no pharmacy can lawfully compound it in the United States, and no laboratory service verifies what arrives. By contrast, the endogenous induction route costs a few dollars a month and is available without restriction. That cost gap carries no payer signal in either direction: neither route is reimbursed by insurers or national health systems, so no institutional payer has a systematic financial incentive to favor one over the other, and the structural bias present in this field runs through the commercial developer of the topical formulation rather than through reimbursement pressure on guideline formation or research funding.
  • Assay availability for monitoring: Plasma hCAP18 and LL-37 are measured almost exclusively by research enzyme-linked immunosorbent assay, not by routine clinical laboratories, and different assay kits are not cross-calibrated, so absolute values cannot be compared across sources. This means the biomarker most directly relevant to the intervention is the one least accessible, and monitoring falls back on vitamin D status and inflammatory markers.

Interaction with Foundational Habits

  • Sleep: Indirect and bidirectional. Neutrophil trafficking and granule content follow a circadian rhythm, and cathelicidin expression tracks it, so sleep disruption that flattens that rhythm plausibly lowers effective peptide availability at the times of day when barrier challenge is greatest. In the reverse direction, sleep quality is measurably worse in rosacea, a condition driven by excess cathelicidin fragments, and rosacea severity correlates with the degree of sleep disturbance. Practically, this means that anyone with a cathelicidin-associated skin condition should expect topical use to interact with sleep quality, and that sleep restriction is a plausible reason for an induction strategy to underperform its expected effect.
  • Nutrition: Direct and mechanistically specific. Butyrate produced by colonic bacteria from fermentable fiber induces the cathelicidin gene through histone deacetylase inhibition, entirely independently of vitamin D, so fiber intake is a genuine dietary lever on endogenous peptide. Vitamin D is the other, and cholecalciferol absorption improves by roughly 30–50% when taken with a fat-containing meal, making dosing with the largest meal of the day the practical implementation. In the opposite direction, alcohol raises circulating LL-37 in both acute intoxication and alcohol use disorder while lowering it in liver tissue (Rojas-Pirela et al., 2026), so regular alcohol intake distorts any attempt to interpret a plasma measurement. Preformed vitamin A above roughly 3,000 µg retinol activity equivalents daily antagonizes vitamin D-driven induction and is worth limiting during an induction attempt.
  • Exercise: Indirect and biphasic. Acute exercise transiently raises salivary and plasma LL-37 as part of the neutrophil mobilization that accompanies exertion, which is a potentiating interaction. Sustained heavy training loads, by contrast, are associated with reduced mucosal antimicrobial peptide concentrations and the elevated upper respiratory infection rates seen in endurance athletes, which is a blunting interaction. There is no established timing relationship between exercise and either topical LL-37 application or vitamin D dosing; the practical consideration is that occlusive dressings and sweat under exercise conditions increase local peptide retention and thus local reaction risk.
  • Stress management: Direct and suppressive. Glucocorticoids downregulate cathelicidin gene transcription, and psychological stress raises endogenous cortisol, which reduces skin antimicrobial peptide expression and is one of the mechanisms by which stress delays wound healing in controlled human studies. The direction is unambiguously blunting for the induction route. The practical consideration is that a period of high sustained stress is the worst time to judge whether a vitamin D or butyrate induction strategy is working, and that stress reduction acts on the same transcriptional lever rather than through a separate pathway.

Monitoring Protocol & Defining Success

Before any use of cathelicidin LL-37 — whether supplied as peptide or pursued through endogenous induction — a baseline panel establishes both the starting position on the pathways the peptide acts through and the contraindication screen. The essential baseline elements are vitamin D status, an inflammatory marker, a full blood count with differential, a lipid panel including apolipoprotein B and lipoprotein(a), and, where the history is ambiguous, autoimmune serology. A full-body skin examination belongs to the same baseline, since new cutaneous lesions are the adverse event most likely to appear.

Ongoing monitoring follows a front-loaded cadence: inflammatory and skin assessment at 4 weeks, the full panel repeated at 12 weeks, and thereafter every 6–12 months for anyone continuing an induction strategy indefinitely. Serum calcium is checked at 12 weeks whenever cholecalciferol above 2,000 IU daily is used.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
25-hydroxyvitamin D 40–50 ng/mL Sets the substrate for cathelicidin gene induction and predicts who can respond Conventional laboratories flag deficiency only below 20 ng/mL and report 30–100 ng/mL as normal; the functional target is narrower at both ends. Non-fasting. Best paired with serum calcium and intact parathyroid hormone. Response takes 8–12 weeks to plateau.
Serum calcium (albumin-corrected) 9.0–9.8 mg/dL Detects the one dose-limiting toxicity of the vitamin D induction route Conventional range extends to 10.5 mg/dL; values in the upper conventional range warrant dose reduction. Fasting preferred. Pair with intact parathyroid hormone, which falls before calcium rises.
Intact parathyroid hormone 15–35 pg/mL Confirms vitamin D sufficiency at the tissue level rather than the assay level Conventional range extends to 65 pg/mL; values above 35 pg/mL with adequate 25-hydroxyvitamin D suggest magnesium insufficiency or renal impairment. Draw in the morning, fasting; levels vary through the day.
Plasma hCAP18/LL-37 500–800 ng/mL by research immunoassay The direct readout of the pathway being manipulated Available only through research enzyme-linked immunosorbent assay, not routine clinical laboratories, and kits are not cross-calibrated, so only within-laboratory changes are interpretable. High values coexist with low tissue expression in active infection, so a high result is not a success signal.
High-sensitivity C-reactive protein Below 0.5 mg/L Flags whether the inflammatory system is already activated, which shifts the risk balance unfavorably Conventional cardiovascular cutoffs treat below 1.0 mg/L as low risk and up to 3.0 mg/L as average; the functional target is stricter. Invalid within 2 weeks of any infection or injury. Fasting not required.
Apolipoprotein B Below 80 mg/dL Quantifies the particles the peptide drives into plaque macrophages Conventional reporting often omits it in favor of low-density lipoprotein cholesterol, which underestimates risk in insulin-resistant people. Fasting not required. Best paired with lipoprotein(a) once in a lifetime.
Lipoprotein(a) Below 75 nmol/L Identifies a genetically fixed atherosclerosis risk that compounds the peptide’s lipid-handling effect Conventional laboratories treat 125 nmol/L as the threshold for elevated risk; the functional target is stricter. Measured once; largely genetically determined and not modified by lifestyle. Report in nmol/L rather than mg/dL where possible, as the two are not reliably interconvertible.
Complete blood count with differential Absolute neutrophil count 1.8–4.0 ×10⁹/L Neutrophils are the main reservoir of the precursor protein, so their number bounds endogenous supply Conventional lower limit is 1.5 ×10⁹/L. Draw in the morning; counts rise through the day and after exertion. Pair with the lymphocyte count, which fell in one melanoma trial participant.
Antinuclear antibody Negative at 1:80 dilution Screens for the systemic autoimmunity in which LL-37 is a target antigen Only warranted where history or symptoms raise the question; a low-titre positive result occurs in 10–15% of healthy adults and is not by itself diagnostic. Pair with anti-citrullinated protein antibody where joint symptoms are present.
Serum tryptase Below 8 ng/mL Identifies the expanded mast cell population that predicts severe flushing and wheal reactions Conventional threshold for investigating mastocytosis is 20 ng/mL; the functional threshold is lower because the concern is reactivity rather than diagnosis. Draw at baseline, not during a reaction.

Qualitative markers matter more here than in most interventions, because the accessible laboratory measures are indirect and the clinically important events are visible ones:

  • Appearance of the application or injection site at 24, 48, and 72 hours, with attention to whether erythema is resolving or persisting
  • Any new verrucous, warty, blistering, or scaly lesion anywhere on the body, which was the presentation of the documented serious toxicity
  • Facial flushing, burning, or stinging, which would indicate the rosacea mechanism becoming active
  • Itching, hives, or wheals appearing within minutes to hours of application, indicating mast cell degranulation
  • Rate of wound edge advance and granulation quality where a wound is the target, photographed under consistent lighting at weekly intervals
  • Frequency and duration of upper respiratory infections over a season, which is the outcome the induction route is usually pursued for
  • New joint pain, morning stiffness, or unexplained rash, which would raise the autoimmune concern
  • Energy, sleep quality, and cognitive clarity, which are non-specific but are the markers most likely to register a systemic inflammatory response early

Success for the topical route is defined as measurable wound area reduction by 4 weeks without persistent application-site inflammation. Success for the induction route is defined as 25-hydroxyvitamin D in the 40–50 ng/mL range with stable calcium and no rise in high-sensitivity C-reactive protein. Absence of new cutaneous lesions and stable apolipoprotein B are the safety definitions of success for both.

Emerging Research

  • Vitamin D, omega-3 fatty acids, and cathelicidin in a large randomized population: The VITAL Infection ancillary study is examining whether 2,000 IU daily vitamin D3 or 1 gram daily omega-3 fatty acids alters infection risk and plasma hCAP18 among 25,874 participants of the parent VITamin D and OmegA-3 TriaL, with primary outcomes of upper respiratory infection and hCAP18 and primary completion scheduled for December 2026 (NCT01758081). This is by an order of magnitude the largest dataset that will ever have addressed whether raising cathelicidin through vitamin D translates into fewer infections in a general adult population, and it is positioned to weaken the case as easily as strengthen it — the parent trial found no effect of vitamin D on its primary cancer and cardiovascular endpoints.
  • Cathelicidin as a downstream marker of biologic therapy in airway disease: A phase 4 study at the University of Virginia is testing whether interleukin-4 receptor alpha blockade with dupilumab reduces Staphylococcus aureus colonization in chronic rhinosinusitis with nasal polyposis, with expression of cathelicidin LL-37 and beta-defensins as secondary endpoints in 20 participants, recruiting with primary completion in June 2026 (NCT05094570). It would establish whether an approved immunomodulator can raise mucosal cathelicidin as a side effect, which would be a far more tractable route than injecting the peptide.
  • Inhaled corticosteroids, air pollution, and antimicrobial host defense proteins: A phase 4 crossover study at the University of British Columbia will expose 48 people with chronic obstructive pulmonary disease to diesel exhaust with and without inhaled corticosteroid, measuring antimicrobial host defense proteins and neutrophil extracellular trap formation among its primary outcomes, with primary completion scheduled for December 2026 (NCT06552364). This directly tests the corticosteroid suppression mechanism in a real human exposure model and could quantify a drug interaction that is currently only inferred from cell culture.
  • Cathelicidin in peri-implant disease: An observational study at Recep Tayyip Erdoğan University will measure 25-hydroxyvitamin D3 and LL-37 in peri-implant sulcus fluid across 72 participants with peri-implant health, mucositis, and peri-implantitis, with primary outcomes of probing pocket depth and clinical attachment level and primary completion in April 2026 (NCT07280754). It extends the best-characterized human tissue for cathelicidin biology, the mouth, into the implant setting.
  • Areas that could strengthen the case — resolving the conflicting wound trials: The Indonesian trial of 0.5 mg/mL LL-37 cream in 40 patients with diabetic foot ulcers reproduced the direction of the venous leg ulcer result in an independent population, a different wound type, and without commercial sponsorship (Miranda et al., 2023; NCT04098562). Against that sit the null results of the 148-participant phase IIb venous leg ulcer trial, whose only positive finding was a post-hoc signal in wounds of at least 10 cm² (Mahlapuu et al., 2021). A trial adequately powered for complete closure in large wounds specifically is the single piece of evidence that would settle which of the two results generalizes, and no such trial is currently registered.
  • Areas that could weaken the case — the atherosclerosis mechanism: The demonstration that LL-37 loads macrophages with low-density lipoprotein through three separate receptors, enlarges plaque in mice engineered to express the human peptide, and correlates with oxidized phospholipid on apolipoprotein B in people with cardiovascular disease is recent enough that no prospective human cohort has yet tested whether circulating LL-37 predicts cardiovascular events (Nakamura et al., 2024). Because the effect is specific to human and primate cathelicidins and absent in mouse and rabbit versions, existing animal safety data cannot be relied upon, and a positive prospective finding would substantially change the risk assessment for older adults.
  • Areas that could weaken the case — the autoantigen mechanism: Work on post-translational modification of LL-37, particularly citrullination and carbamylation, indicates that modified forms drive distinct autoreactive T-helper phenotypes and are recognized by autoantibodies in lupus and rheumatoid arthritis (Lande et al., 2014 established the parent finding in psoriasis). Whether administered synthetic peptide undergoes the same modification in inflamed human tissue is unknown and is the single most important unresolved safety question for anyone injecting it.
  • Areas that could strengthen the case — engineered analogues: Shorter, more protease-resistant derivatives of LL-37 are being developed through truncation, residue substitution and cyclization to retain antimicrobial and immunomodulatory activity while lowering host toxicity (Dave & Thapa, 2026), and the specific sequence stretch that binds nucleic acids and drives the inflammatory response has now been mapped, which is what makes removing it a tractable design target (Kulkarni et al., 2021). If a derivative can be shown to separate the two functions, the risk profile described throughout this review would apply to the parent peptide but not to its successor, and the therapeutic case would rest on entirely new evidence.

Conclusion

Cathelicidin LL-37 is a natural defense peptide the human body makes and stores in immune cells and in the linings of the skin, gut, and airways. Its ability to break open microbes, clear debris, and speed the closing of wounds is well documented in laboratory work. Human testing is thin and points both ways: two small controlled trials of skin preparations on stubborn wounds found faster healing, but a much larger trial run by the company developing it found no advantage over a placebo cream outside an unplanned analysis of the largest wounds.

The properties that make the peptide useful also make it hazardous. When it binds fragments of a person’s own genetic material it turns the immune system against the body’s own tissue, a process tied to scaly skin disease, facial flushing disorders, and lupus. It pushes cholesterol into the cells that build fatty deposits in arteries, and it feeds the growth of some tumors while restraining others. Regulators reviewing it as an ingredient for pharmacy-made preparations noted both a lack of human safety data and laboratory signals of tumor promotion and harm to male fertility.

What is best characterized is not the supplied peptide but the factors governing the body’s own production, chiefly vitamin D status and what gut bacteria make from dietary fiber. The balance of benefit and harm also differs sharply from person to person: someone with inflamed skin, autoimmune disease, or established artery narrowing carries a very different one than someone without.

Top - Benefits - Risks - Protocol